secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2022-06-13T23:59:59+00:00
Accession:  0001193125-22-172425
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx receives first global approval: Health Canada approves ALBRIOZA for ALS
------------------------------------------------------------------------------

- Health Canada approved ALBRIOZA (AMX0035) with conditions for ALS; first marketing approval worldwide.
- Approval based on Phase 2 CENTAUR trial showing 2.32-point higher ALSFRS-R score vs placebo over 24 weeks.
- Condition requires data from ongoing Phase 3 PHOENIX trial; topline results expected in 2024.
- ALBRIOZA expected to be commercially available in Canada within six weeks.
- FDA PDUFA date set for Sept 29, 2022; EMA application under review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312522172425/0001193125-22-172425-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312522172425/d358853d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-172425

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer